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Using the fluconazole–zidovudine (AZT) interaction as a model, to determine whether








 kinetic data generated in the presence




Kinetic constants for AZT glucuronidation were generated using human liver
microsomes (HLM) and recombinant UGT2B7, the principal enzyme responsible for
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. Fluconazole, which was shown to be a
selective inhibitor of UGT2B7, competitively inhibited AZT glucuronidation by HLM








































 values determined for fluconazole using HLM and UGT2B7 in the





magnitude of the interaction ranged from 41% to 217% of the reported AUC increase













 values determined under certain experimental conditions may quantitatively predict








Inhibition  of  drug  metabolism  by  a  coadministered
drug results in decreased metabolic clearance and/or
increased bioavailability. The elevated blood concentra-
tion of the parent drug may result in an enhanced and
prolonged pharmacological response, with an increased
likelihood of drug-induced toxicity. Indeed, drug inter-
actions are a well-recognized cause of adverse events,
within both hospitals and community-based practices
[1]. Thus, the ability to predict inhibitory drug interac-
tions is an essential consideration for the safe and effi-
cacious use of medicines. Moreover, several drugs have
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been withdrawn from the market in recent years due to
the occurrence of fatal inhibitory drug interactions.
Apart from quality use of medicines issues, inhibitory
drug interactions also represent a potential economic
loss for the pharmaceutical industry [2].
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 has found increasing acceptance in








) for a metabolic pathway,
generally determined from microsomal or hepatocyte





) and extraction ratio using a mathematical











), have also been investigated as a










potentially provide a cost-effective approach for
screening inhibitory drug interactions, with reduced





 approaches have been used to predict interac-
tions between drugs metabolized by cytochrome P450









interactions involving glucuronidated drugs has not
been explored in a systematic manner.
Glucuronidation involves the covalent linkage of a
suitable functional group present on the substrate with
glucuronic acid (derived from the cofactor UDP-
glucuronic acid). The glucuronidation reaction is cat-
alysed by the enzyme UDP-glucuronosyltransferase
(UGT). Like CYP, UGT exists as an enzyme superfam-
ily; 17 human UGT enzymes have been identified to
date. The functional human UGTs exhibit distinct, but
frequently overlapping, substrate and inhibitor selectiv-
ities [12]. Consistent with this heterogeneity, glucu-
ronidation serves as an elimination mechanism for a
myriad of structurally diverse endogenous compounds
and xenobiotics, including many clinically used drugs.




are well documented [13, 14].
Zidovudine (AZT) is cleared primarily by glucu-
ronidation in humans [15–17] and a number of drugs












apparent oral clearance of AZT by glucuronidation by
47.1% (corresponding to a 1.92-fold increase in the
mean area under the AZT plasma concentration–time
curve (AUC) associated with clearance by glucuronida-










well characterized and hence this compound represents









lation. In particular, the kinetics of AZT glucuronida-
tion by human liver microsomes (HLM) have been
determined over a range of experimental conditions and
a single enzyme, UGT2B7, has been shown to be
responsible for AZT glucuronide (GAZT) formation
[19, 20].
Previous investigations conducted in this laboratory





determined for AZT glucuronidation by HLM under-




 hepatic AZT clearance by
glucuronidation, and this observation appeared consis-
tent for other glucuronidated drugs [19]. It has been
reported that the addition of bovine serum albumin





ues for several drugs metabolized by cytochrome











. Although the mechanism
of the albumin effect is unknown and the addition of
albumin to microsomal incubations may appear




 obtained under these








 extrapolation and thus warrants further investi-
gation. At present, the effect of BSA on the kinetics of












 value determined for inhibition of AZT glucuronida-
tion by fluconazole, using both HLM and UGT2B7 as





. Additionally, the work
sought to: (i) characterize the selectivity of fluconazole
as an inhibitor of human UGTs by screening for effects
on individual recombinant enzymes, and (ii) determine
the effects of exogenous albumin (as BSA) on the kinet-
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luoperazine (TFP; dihydrochloride salt), trifluoroacetic
acid, UDP-glucuronic acid (UDPGA; trisodium salt)
and cellulose dialysis membrane (molecular weight cut-
off 12 000 Da) were purchased from Sigma-Aldrich Pty
Ltd (Sydney, Australia). Fluconazole was a gift from
Pfizer Australia (Sydney, Australia). Solvents and other
reagents were of analytical reagent grade.
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Human liver microsomes and expression of UGT protein
 
Human livers (HL 10, 12, 13 and 40) were obtained
from the human liver ‘bank’ of the Department of Clin-
ical Pharmacology, Flinders Medical Centre. Approval
was obtained from the Flinders Medical Centre
Research Ethics Committee and from the donor next-of-
kin for the procurement and use of human liver tissue
in xenobiotic metabolism studies. Microsomes were





 [24], and activated by the addition of











protein) with preincubation on ice for 30 min [19] prior
to use in incubations.
UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10,
2B7 and 2B15 cDNAs were stably expressed in a human
embryonic kidney cell line (HEK293), as described pre-
viously [25–27]. Cells were separately transfected with
the individual UGT cDNAs cloned into the pEF-IRES-
puro6 expression vector and incubated in Dulbecco’s
modified Eagle’s medium (DMEM), which contained






), 10% fetal calf serum and peni-

















) in a humidified incubator with an atmo-








C. After growth to at least 80%
confluency, cells were harvested and washed in phos-
phate-buffered saline. The harvested cells were lysed by
sonication using a Heat Systems-Ultrasonics sonicator
set at microtip limit of 4. Cells expressing UGT1A pro-




 2-s ‘bursts’, each sepa-
rated by 3 min cooling on ice. Sonication was limited to
1-s ‘bursts’ for UGT2B subfamily proteins, due to their
apparently greater thermolability. The lysed samples




 for 1 min at 4°C and the
supernatant fraction was separated and stored at −80°C
until use.
4MU glucuronidation assay The activities of recombi-
nant enzymes (viz. UGT 1A1, 1A3, 1A6, 1A7, 1A8,
1A9, 1A10, 2B7 and 2B15) were confirmed with the
nonselective substrate 4MU prior to use in the inhibition
and kinetic studies. 4MU glucuronidation was measured
according to a previously published procedure [28].
Incubations contained UDPGA (5 mM), MgCl2 (5 mM),
HEK293 cell lysate, phosphate buffer (0.1 M, pH 7.4)
and 4MU in a total volume of 0.6 ml. Reaction times
and lysate protein concentrations for incubations with
each individual isoform were as reported by Sorich et al.
[25] for UGT1A1 and Uchaipichat et al. [27], for UGT
1A3, 1A6, 1A7, 1A8, 1A9, 1A10, 2B7 and 2B15.
Within-day 4MUG assay imprecision, determined by
measuring product formation in five separate incuba-
tions using HLM as the enzyme source, was <4% for
4MU concentrations in the range 20–2000 µM.
TFP  glucuronidation  assay TFP was used as the
substrate for UGT1A4. Trifluoperazine glucuronide
(TFPG) formation was measured using a modification
of  the  method  recommended  by  BD  Gentest  (http:
//www.bdbiosciences.com/discovery_labware/gentest/
products/pdf/1A4_AAPS_S01T056R1.pdf). The incu-
bation mixture (0.2 ml total volume) contained Tris–
HCl buffer (50 mM, pH 7.4), UDPGA (5 mM), MgCl2
(5 mM), UGT1A4 HEK293 cell lysate (0.25 mg ml−1),
and TFP. Reactions were initiated by the addition of
UDPGA and incubations were performed at 37°C in a
shaking water bath for 20 min. Incubations were termi-
nated by the addition of 4% acetic acid/96% methanol
(0.2 ml) and then centrifuged at 5000 g for 10 min. A
40-µl aliquot of the supernatant fraction was injected
into the high-perfromance liquid chromatography
(HPLC) column.
Measurement  of  TFPG  formation HPLC was per-
formed using an Agilent 1100 series instrument (Agilent
Technologies, Sydney, NSW, Australia) fitted with an
Ultrasphere ODS column (4.6 × 250 mm, 5 µm; Beck-
man Instruments, Fullerton, CA, USA). Analytes were
separated using a linear gradient with flow rate of
1 ml min−1. Initial conditions were 70% 0.1% trifluoro-
acetic acid/water (mobile phase A) and 30% 0.1% trif-
luoroacetic acid in acetonitrile (mobile phase B). The
proportion of mobile phase B was increased to 50% over
10 min. Column eluant was monitored by UV absor-
bance 256 nm. Under these conditions, retention times
of TFPG and TFP were 9.1 and 9.8 min, respectively.
TFPG was quantified by comparison of peak areas with
those of a TFP external standard curve prepared over the
concentration range 0.2–10 µM. There is evidence dem-
onstrating that the absorption characteristics of aliphatic
N+-glucuronides are similar to the aglycone [29] (http:
//www.bdbiosciences.com/discovery_labware/gentest/
products/enzym_micro/prod_inserts/p414.shtml). Within-
day overall assay reproducibility was assessed by
measuring TFPG formation in eight separate incuba-
tions of the same batch of pooled HLM (from HL 10,
12, 29 and 40). Coefficients of variation were 3.8% and
5.2% for added TFP concentrations of 10 and 200 µM,
respectively.
The identity of TFPG was confirmed by enzymatic
and base hydrolysis. A 0.2-ml TFP glucuronidation
incubation (see above) was terminated with 70% HClO4
(2 µl) and centrifuged. The aqueous sample was
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decanted and mixed with 20 µl of 1 M phosphate buffer
(pH 7.4) (to raise the pH to 6.5) and 1800 units of β-
glucuronidase. After 2 h incubation at 37°C, a 150-µl
aliquot was separated and treated with 70% HClO4
(5 µl). Base hydrolysis was performed by adding an
equal volume of 4 M NaOH to a 0.2-ml TFP glucu-
ronidation incubation and heating at 75°C for 45 min,
after which time a 150-µl aliquot was separated and
treated with 70% HClO4 (40 µl). Following centrifuga-
tion (5000 g for 10 min), 40 µl of the supernatant frac-
tion from each reaction was injected into the HPLC
column. Both treatments resulted in loss of the TFPG
peak in the chromatogram.
AZT glucuronidation assay GAZT formation was mea-
sured using a modification of the method of Boase and
Miners [19]. Incubation mixtures, in a total volume
0.2 ml, contained phosphate buffer (0.1 M, pH 7.4),
MgCl2 (4 mM), UDPGA (5 mM), AZT (50–4000 µM)
and activated HLM (1 mg ml−1) or UGT2B7 HEK293
cell lysate (1.5 mg ml−1). Reactions were initiated by the
addition of UDPGA and performed at 37°C in a shaking
water bath for 60 min. Following the addition of 24%
HClO4 (10 µl), samples were centrifuged (5000 g for
10 min) and 30 µl of the supernatant fraction was
injected into the HPLC column.
For reactions carried out in the presence of 2% BSA,
incubation mixtures contained AZT in the concentration
range 10–1000 µM due to a lower Km. Incubation con-
ditions were as described for reactions in the absence of
BSA, except that the protein amount and incubation
time for HLM were 0.25 mg ml−1 and 30 min, respec-
tively. Due to the higher protein concentration, reactions
were terminated by addition of 10 µl of 70% HClO4. A
0.12-ml aliquot of the supernatant fraction was trans-
ferred to a 1.5-ml Eppendorf tube containing 4 M KOH
(10 µl), mixed and centrifuged at 10 000 g for 1 min.
Thirty microlitres of the supernatant fraction was
injected into the HPLC column.
Measurement  of  GAZT  formation HPLC was per-
formed using an Agilent 1100 series instrument fitted
with a SecurityGuard C18 cartridge (4 × 3 mm; Phenom-
enex, Sydney, Australia) and a NovaPak C18 column
(3.9 × 150 mm; Waters Associates, Milford, MA, USA).
The mobile phase, 0.12% v/v acetic acid in 10% aceto-
nitrile/water, was delivered at a flow rate 1.2 ml min−1.
Column eluant was monitored by UV absorbance at
267 nm. Retention times of GAZT and AZT were 3 and
6.2 min, respectively. Concentrations of GAZT in incu-
bation samples were determined by comparison of peak
areas with those of GAZT standard curve with concen-
trations in the range 1–20 µM. Overall assay reproduc-
ibility, assessed by measuring GAZT formation in 10
separate incubations of the same batch of HLM, was
3.7%, 2.1% and 2.5% for added AZT concentrations of
50 µM, 1000 µM and 3000 µM, respectively.
Fluconazole  inhibition  of  recombinant  UGTs The
selectivity of UGT inhibition by fluconazole was
assessed using 4MU or TFP as the substrate. 4MU was
employed as the substrate for the inhibition studies with
UGT 1A1, 1A3, 1A6, 1A7, 1A8, 1A9, 1A10, 2B7 and
2B15, whereas TFP was used as the substrate for
UGT1A4. Incubations with 4MU were performed at the
concentration corresponding to the apparent Km or S50
value reported for each isoform (viz. 100, 1000, 100, 15,
750, 10, 40, 350 and 300 µM for UGT 1A1, 1A3, 1A6,
1A7, 1A8, 1A9, 1A10, 2B7 and 2B15, respectively) [25,
27]. The concentration of TFP used in incubations with
UGT1A4 was 40 µM, which corresponds to the Km for
this substrate [30]. Concentrations of fluconazole used
in the screening experiments were 0, 10, 100, 500, 1000
and 2500 µM.
Fluconazole  inhibition  of  AZT  glucuronidation Flu-
conazole inhibition of AZT glucuronidation was inves-
tigated using microsomes from four human livers and
with UGT2B7 HEK293 cell lysate, in the presence and
absence of BSA (2%), using the incubation and assay
conditions described previously. Experiments per-
formed to determine inhibitor constants (Ki) for flucon-
azole included four inhibitor concentrations at each of
three AZT concentrations.
Binding  of  AZT  and  fluconazole  to  BSA,  human  liver 
microsomes and HEK293 cell lysate Binding of AZT
and fluconazole to BSA, HLM and HEK293 cell lysate
and to combinations of BSA with each enzyme source
was investigated using an equilibrium dialysis method
[31]. One side of the dialysis apparatus contained phos-
phate buffer (0.1 M, pH 7.4), AZT (four to eight concen-
trations in the range 20–1000 µM) or fluconazole (four
concentrations in the range 25–500 µM) and pooled
microsomes (0.25 mg ml−1) from the four human livers
used in kinetic studies or BSA (2%) or HEK293 cell
lysate (1.5 mg ml−1) or the combination of BSA with
each enzyme source in a total volume of 1 ml. The other
compartment contained phosphate buffer (1 ml) alone.
The dialysis cell assembly was immersed in a water bath
maintained at 37°C and rotated at 12 r.p.m. for 3 h.
Control experiments were also performed with buffer or
BSA or HLM or HEK293 cell lysate or the combination
of BSA with each enzyme source on both sides of the
Predicting inhibition of drug glucuronidation
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dialysis cell with high and low concentrations of both
drugs to ensure that equilibrium was attained. A 0.2-ml
sample was collected from each compartment, treated
with 70% HClO4 (10 µl), vortex mixed, and centrifuged
(5000 g for 10 min). A 0.12-ml aliquot of the superna-
tant fraction was transferred to a 1.5-ml Eppendorf tube
containing 4 M KOH (10 µl). Mixtures were mixed and
centrifuged at 10 000 g for 1 min. A 5-µl aliquot of the
supernatant fraction was analysed by HPLC. The HPLC
system and conditions for the AZT and fluconazole
assays were essentially identical to those described pre-
viously for the measurement of GAZT, except that the
content of acetonitrile in the mobile phase was increased
by 3% and 15% for the AZT and fluconazole assays,
respectively. Under these conditions, AZT and flucona-
zole eluted at 3.3 and 2.2 min, respectively. Standards
in the concentration range 10–1000 µM (AZT) and 25–
500 µM (fluconazole) were prepared in phosphate buffer
(0.1 M, pH 7.4) and treated in the same manner as dial-
ysis samples. The AZT or fluconazole concentrations of
dialysis samples were determined by comparison of
peak areas with those of the standard curve. Within-day
assay imprecision was assessed by measuring AZT (10
and 500 µM) or fluconazole (50 and 300 µM) in five
replicate samples containing buffer and the combination
of BSA with each enzyme source. Coefficients of vari-
ation in all cases were less than 4%.
Data analysis
AZT and fluconazole kinetic parameters Kinetic con-
stants for AZT glucuronidation by HLM or UGT2B7
HEK293 cell lysate were obtained by fitting experimen-
tal data to the Michaelis–Menten and substrate inhibition
equations [27] using Enzfitter (Biosoft, Cambridge, UK).
The Michaelis–Menten equation is
(1)
where v is the rate of reaction, Vmax is the maximum
velocity, Km is the Michaelis constant (substrate concen-
tration at 0.5 Vmax) and [S] is the substrate concentration.
The substrate inhibition is
(2)
where Ksi is the constant describing the substrate inhi-
bition interaction.
Ki values for fluconazole inhibition of AZT glucu-
ronidation were determined by fitting experimental data
to the expressions for competitive, noncompetitive and
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fit to kinetic and inhibition models was assessed from
the F statistic, r2 values, parameter standard error
estimates and 95% confidence intervals. Kinetic con-
stants are reported as the value ± standard error of the
parameter estimate. All data points shown in    Figures 1–
3 represent the mean of duplicate measurements (which
invariably differed by <10%). The statistical significance
of the effects of BSA on the kinetic parameters Km and
Vmax were assessed using Student’s paired t-test.
Prediction of AZT glucuronidation clearance Microso-
mal AZT glucuronidation intrinsic clearance, CLint, was
calculated as Vmax/Km (units of µl min−1 mg−1 microsomal
protein) and subsequently scaled to the whole liver CLint
assuming a liver weight of 1500 g and a microsome yield
of 45 mg microsomal protein g−1 of liver [3]. In vivo CLH
was then predicted using expressions for the well-stirred,
parallel-tube and dispersion models.
Well stirred model:
(3)
where fu is fraction unbound in blood and QH is liver








CLH = QH (1 − FH)
DN, the dispersion number, may be taken as 0.17 [32]
and a = (1 + 4.RN.DN)1/2. RN, the efficiency, is given by  
The fraction of drug unbound in blood was evaluated
as fu = fu,p /RB, where RB is the blood to plasma concen-
tration ratio and fu,p is the fraction unbound in plasma.
For AZT, fu,p was taken as 0.77 and RB as 0.86 [33]. In
vivo CLH for AZT glucuronidation was taken from the
literature. Mean AZT systemic clearance ranges from 77
to 114 l h−1 per 70 kg [15–17], giving an average value
of 94 l h−1 per 70 kg. Since 80% of the recovered dose
is accounted for as AZT glucuronide in urine, with the
majority of the remainder being unchanged drug [17],
the plasma AZT clearance by glucuronidation in vivo
may be taken as 75 l h−1 per 70 kg. Taking into account
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AZT clearance by glucuronidation calculated from the
plasma clearance and RB was 87 l h−1.
Quantitative prediction of the AZT–fluconazole interaction
The  extent  of  inhibition  of  AZT  hepatic  clearance
by fluconazole (determined as the ratio of the areas
under  the  plasma  AZT  concentration–time  curves with
and without fluconazole coadministration, R = AUC(+flu-
conazole)/AUC(control)), was predicted using the equation for
oral administration of a high hepatic clearance drug [5]:
(6)
where Iu is the unbound fluconazole concentration at the
enzyme active site; fm is the fraction of AZT metabolism
via glucuronidation in the liver, and Ki is the inhibition
constant for fluconazole generated in vitro. The extent
of inhibition was calculated based on the maximum
unbound (Imax,u) and the average unbound (Iav,u) concen-
trations of fluconazole in serum. The average Imax and Iav
values measured in patients who participated in the in
vivo fluconazole–AZT interaction study were 77.7 µM
and 60.1 µM, respectively [18]. (Patients were studied
after 7 days treatment with fluconazole, 400 mg once
daily.) The unbound fraction of fluconazole in plasma
has been reported as 0.89 [34]. In addition to systemic
fluconazole concentrations, the predicted in vivo AUC
ratio was estimated based on the unbound fluconazole
hepatic  inlet  concentration  (Iinlet,u),  calculated  as the
sum of the maximal unbound plasma concentration in
circulating blood (Imax × fu) and the contribution from
gastrointestinal absorption after oral administration
( fu × [ka.Fa.Dose/QH]), assuming that the unbound liver
concentration equates to that in plasma [5]. The Iinlet,u
can be calculated from the equation:
 
(7)
where fu, ka and Fa are the unbound fraction in plasma,
the absorption rate constant and the fraction absorbed
from the gastrointestinal tract into the portal vein,
respectively. The bioavailability of fluconazole is close
to 100% [35]. Values for the absorption rate constant of
fluconazole have been reported by Demuria et al. [35].
Results
Binding of AZT and fluconazole to human liver 
microsomes, HEK293 cell lysate and BSA
The binding of AZT and fluconazole was determined





























divided by the drug concentration in the protein com-
partment, and expressed as the fraction unbound to
incubation constituents ( fuinc). With both AZT and
fluconazole, fuinc was independent of concentration.
Mean data are shown in  Table 1. The binding of
AZT to HLM and HEK293 cell lysate was negligible,
both in the absence and presence of BSA, despite
measurable binding (approximately 5%) to BSA
alone. Similarly, fluconazole did not bind nonspecifi-
cally to HLM or HEK293 cell lysate. However, bind-
ing to BSA (2%), alone and in the presence of HLM
and HEK293 cell lysate, ranged from approximately
10% to 15%. Thus, concentrations of fluconazole
added to incubation mixtures containing BSA were
corrected for binding in experiments that determined
a Ki value.
Inhibition of human UGTs by fluconazole
Fluconazole was screened for inhibition of UGT 1A1,
1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B7 and 2B15
using TFP (UGT1A4) or 4MU (all other enzymes) as
the ‘probe’ substrates. Inhibition was assessed at the
reported Km or S50 value for these substrates with the
respective enzymes. Fluconazole inhibited UGT2B7 in
a concentration-dependent manner (Figure 1). Inhibi-
tion of the other enzymes by fluconazole concentrations
in  the  range  10–1000 µM  was  negligible  or minor
(0–15%). At the highest concentration of fluconazole
assessed (viz. 2500 µM), inhibition of UGT 1A3, 1A4,
1A7, 1A8, 1A9 and 1A10 was ≤14%, although this
concentration of fluconazole inhibited UGT 1A1, 1A6
and 2B15 by approximately 25%.
Table 1
Fraction unbound (fuinc) aof zidovudine (AZT) and 
fluconazole in presence of human liver microsomes, 
HEK293 cell lysate, bovine serum albumin (BSA) (2%) 
and the combination of BSA with each enzyme source
AZT Fluconazole
HLM (0.25 mg ml−1)b 1.042 ± 0.017 1.043 ± 0.020
Lysate (1.5 mg ml−1)c 1.010 ± 0.005 1.016 ± 0.009
BSA (2%) 0.942 ± 0.009 0.848 ± 0.013
HLM + BSA 0.980 ± 0.009 0.919 ± 0.027
Lysate + BSA 0.995 ± 0.016 0.892 ± 0.020
aData presented as mean ± SD. bHLM, human liver
microsomes. cLysate, HEK293 cell lysate.
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Formation and inhibition kinetics of AZT glucuronidation by 
human liver microsomes and UGT2B7
AZT glucuronidation by HLM and UGT2B7 in the
absence of BSA followed Michaelis–Menten kinetics
(Figure 2A,C). Mean (± SD) derived Km and Vmax values
for  the  four  livers  investigated  were  923 ± 357 µM
and 1066 ± 325 pmol min−1 mg−1, respectively  (Table
2). The Km for AZT glucuronidation by UGT2B7 was
478 µM. Kinetic constants for AZT glucuronidation
determined in the absence of BSA are generally similar
to those reported previously for this reaction by this
laboratory [19] and by Court et al. [20]. The addition of
0.2, 2 and 4% BSA increased the rate of AZT glucu-
ronidation (at a substrate concentration of 500 µM) by
2.7-, 3.5- and 3.6-fold, respectively. Thus, subsequent
experiments that investigated the effects of BSA on AZT
glucuronidation kinetics and inhibition by fluconazole
included 2% BSA. Addition of 2% BSA to incubations
caused a 90% reduction in the mean Km (to 91 ± 9 µM)
for AZT glucuronidation by HLM, without significantly
affecting Vmax (1166 ± 484 pmol min−1 mg−1) (Table 2).
Similarly, BSA (2%) caused an approximately 85%
reduction in the Km (to 70 µM) for AZT glucuronidation
by UGT2B7, with only a minor effect on Vmax (19%
Figure 2 
Representative Eadie–Hofstee plots for 
zidovudine (AZT) glucuronidation by: (A) 
human liver microsomes (HL40) in the 
absence of bovine serum albumin (BSA); (B) 
human liver microsomes (HL40) in the 
presence of BSA; (C) UGT2B7 in the absence 
of BSA; and (D) UGT2B7 in the presence of 
BSA. Points are experimentally determined 
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Figure 1 
Effect of fluconazole (10–2500 µM) on the activity of human UDP-
glucuronosyltransferases (UGTs). Each bar represents the mean 
percentage activity relative to control from duplicate measurements. 
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reduction) (Table 2). Interestingly, AZT glucuronidation
by UGT2B7 in the presence of BSA exhibited weak
substrate inhibition (Ksi 5168 µM), whereas the kinetic
model for this reaction by HLM (i.e. Michaelis–
Menten) was not changed by BSA (Figure 2B,D). When
considered in terms of intrinsic clearance, BSA
increased this parameter 10-fold and 5.7-fold for the
human liver microsomal and UGT2B7 catalysed reac-
tions, respectively (Table 2).
Fluconazole was a competitive inhibitor of AZT
glucuronidation  by  HLM  and  UGT2B7  (Figure 3).
The respective Ki values determined in the absence of
BSA were 1133 ± 403 µM (mean ± SD) and 529 µM
(Table 3). The addition of BSA (2%) caused an 86%
reduction in the Ki values for fluconazole inhibition of
AZT glucuronidation by HLM (to 145 ± 36 µM) and by
UGT2B7 (to 73 µM) (Table 3).
In vitro–in vivo correlation
The microsomal CLint values for AZT glucuronidation
shown in Table 2 were extrapolated to blood AZT
hepatic clearances as described in Data analysis. For
kinetic constants determined in the absence of BSA,
mean (± SD) predicted hepatic AZT clearances by glu-
curonidation calculated using the well-stirred (equation
3), parallel-tube (equation 4) and dispersion (equation
5) models were 3.29 ± 1.45 l h−1, 3.35 ± 1.51 l h−1 and
3.33 ± 1.49 l h−1, respectively. For kinetic constants
determined in the presence of BSA, respective predicted
hepatic clearances calculated using the three models
were 24.2 ± 7.34 l h−1, 28.0 ± 9.7 l h−1 and 26.8 ± 8.9 l
h−1. As noted in Data analysis, the reported mean hepatic
AZT clearance by glucuronidation is approximately
87 l h−1 per 70 kg.
Similarly, the predicted in vivo ratios of the AZT AUC
values in the presence and absence of fluconazole were
estimated from the Ki values shown in Table 3 using
equation 6 (Data analysis). Since glucuronidation is
responsible for all but a very minor proportion of hepatic
clearance, fm (the fraction of the metabolic process sub-
ject to inhibition) was taken as 1. The in vivo AUC ratio
was calculated using several estimates of the unbound
concentration of inhibitor (i.e. fluconazole); Imax,u, Iav,u
and Iinlet,u (Data analysis). The expression for the latter
Table 2
Kinetic constants for zidovudine (AZT) glucuronidation by alamethicin-treated human liver microsomes and UGT2B7 in the 
absence and presence of bovine serum albumin (BSA)














HL10 743 ± 2.9 731 ± 0.9 0.98 94 ± 0.01 782 ± 0.03 8.3
HL12 1133 ± 24 1503 ± 12 1.33 90 ± 1.1 1876 ± 8.9 20.8
HL13 1299 ± 17 949 ± 5.5 0.73 103 ± 0.5   999 ± 1.8 9.7
HL40 518 ± 1.4 1082 ± 0.8 2.09 80 ± 0.5 1009 ± 2.2 12.6
UGT2B7 478 ± 14 43 ± 0.5 0.09 70 ± 2.3 36 ± 0.6 0.51
aData presented as mean ± SE of parameter fit. bBest fit to Michaelis–Menten model for all data. cBest fit to Michaelis–Menten
model for all data except for UGT2B7, which was fitted to the substrate inhibition expression (Ksi 5168 ± 596 µM). dCLint calculated
as Vmax /Km. eKm values expressed as unbound AZT.
Table 3
Inhibitor constants for fluconazole inhibition of zidovudine 
(AZT) glucuronidation by alamethicin-treated human liver 
microsomes and UGT2B7 in the absence and presence of 





HL10 893 ± 12 125 ± 7.6
HL12 1309 ± 61 134 ± 1.5
HL13 1609 ± 32 199 ± 6.7
HL40 719 ± 22 122 ± 5.2
UGT2B7 529 ± 46 73 ± 2.3
aCompetitive  inhibition.  bData  presented  as  mean  ±  SE
of parameter fit. cKi values expressed as unbound
fluconazole.
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includes the absorption rate constant, ka. Three different
values of ka were used to calculate Iinlet,u: the maximum
and average values reported in vivo (viz. 0.0318 and
0.0164 min−1) [35] and 0.1 min−1, which is the theoreti-
cal maximum assuming absorption is rapid and gastric
emptying rate is rate-limiting [5, 11]. Predicted AUC
ratios are shown in  Table 4. The known mean AUC ratio
(viz. 1.92; see Introduction) associated with the AZT–
fluconazole interaction was underpredicted (by 85–
95%) using Ki values determined with both HLM and
UGT2B7 as the enzyme source in the absence of BSA.
However, the use of Ki values determined in the pres-
ence of BSA predicted mean AUC ratios ranging from
1.38 to 2.05 and 1.73 to 3.0 with HLM and UGT2B7 as
the enzyme sources, respectively (Table 4).
Discussion
The magnitude of an inhibitory drug interaction in vivo
may theoretically be predicted from the ratio of the
inhibitor concentration and the inhibition constant (Ki).
Figure 3 
Representative Dixon plots for fluconazole 
inhibition of zidovudine (AZT) glucuronidation 
by: (A)human liver microsomes (HL40) in the 
absence of bovine serum albumin (BSA) 
250 µM AZT (), 500 µM AZT (), 750 µM 
AZT (); (B) human liver microsomes (HL40) 
in the presence of BSA, 60 µM AZT (), 80 µM 
AZT (), 100 µM AZT (); (C) UGT2B7 in the 
absence of BSA, 200 µM AZT (), 400 µM AZT 
(), 600 µM AZT (); and (D) UGT2B7 in the 
presence of BSA, 25 µM AZT (), 50 µM AZT 
(), 75 µM AZT (). Points are experimentally 
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Prediction of in vivo interaction between zidovudine (AZT) and fluconazole (cf. observed in vivo AUC ratio of 1.92)
BSA (2%) Enzyme source Ki (µM)
Predicted AUC ratio based on
Imax,u Iav,u Iinlet,ua Iinlet,ub Iinlet,uc
Absent HLM (mean ± SD) 1132 ± 402 1.07 ± 0.02 1.05 ± 0.02 1.08 ± 0.03 1.09 ± 0.03 1.14 ± 0.05
UGT2B7 529 1.13 1.10 1.15 1.18 1.28
Present HLM (mean ± SD) 145 ± 36 1.49 ± 0.10 1.38 ± 0.08 1.59 ± 0.12 1.67 ± 0.14 2.05 ± 0.21
UGT2B7 73 1.94 1.73 2.11 2.28 3.0
aka = 0.01635 min−1 (Demuria et al. [34]).bka = 0.03183 min−1(Demuria et al. [34]).cka = 0.1 min−1(Ito et al. [4]).
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Although values of Ki determined in vitro, typically
using HLM as the enzyme source, have been used to
predict interactions arising from inhibition of CYP-
mediated drug metabolism [2, 4–6, 8–11], the applica-
tion of this approach to glucuronidated drugs has
received less attention. Thus, we investigated whether
interactions arising from inhibition of UGT-catalysed
drug metabolism could be determined quantitatively
from in vitro kinetic data using the fluconazole–AZT
interaction as the model. It was demonstrated that the in
vivo interaction may be predicted from in vitro inhibi-
tion data, generated using both HLM and recombinant
UGT2B7, but only for Ki values determined in the pres-
ence of BSA.
Initial studies investigated the selectivity of human
UGT inhibition by fluconazole. Fluconazole was a rel-
atively selective inhibitor of UGT2B7, and this provides
a mechanistic basis for the AZT–fluconazole interaction
since AZT is known to be glucuronidated almost exclu-
sively by UGT2B7 [20]. This observation also indicates
that fluconazole may be of use for the reaction pheno-
typing of human liver microsomal xenobiotic glucu-
ronidation by this UGT2B7. Subsequent experiments
showed that fluconazole inhibition of AZT glucuronida-
tion by both HLM and UGT2B7 was competitive. This
is consistent with the observation that a small proportion
(viz. 6.5%) of orally administered fluconazole is recov-
ered as fluconazole glucuronide in humans [36].
The addition of BSA, at least at low concentrations,
to microsomal incubations has been shown to increase
the CLint values, via a reduction in Km, of several drugs
metabolized by CYP2C9 [21–23]. Furthermore, BSA
(1.8–2.25%) has been reported to enhance the rates of
human liver microsomal AZT and fenoldopam glucu-
ronidation, up to 15-fold [37, 38]. Here, BSA (2%)
increased the mean CLint for human liver microsomal-
and UGT2B7-catalysed AZT glucuronidation by 10- and
5.7-fold, respectively, due primarily to a reduction in Km.
Apart from predicting the extent of inhibitory drug
interactions, quantitative in vitro–in vivo extrapolation
has been employed extensively to calculate in vivo CLH
from CLint determined in vitro. Typically, the CLint
obtained from microsomal or hepatocyte kinetic data is
scaled to a whole liver value and then substituted in the
mathematical expressions for models of hepatic clear-
ance. Although the validity of this strategy has been
demonstrated for some drugs eliminated by CYP, the
approach underpredicts the CLH of AZT and other glu-
curonidated drugs by one to two orders of magnitude
[12, 19, 39, 40]. Despite the increase in microsomal
CLint for GAZT formation in the presence of BSA,
values of AZT glucuronidation hepatic clearances
determined using the well-stirred, parallel-tube and dis-
persion models still underpredicted the reported mean
in vivo CLH for AZT glucuronidation by approximately
3.5-fold. While the difference between the predicted and
known in vivo CLH was decreased using in vitro kinetic
data generated in the presence of BSA, AZT was not
predicted to be a ‘high’ hepatic clearance drug. (It
should be noted that, while different scaling factors have
been reported for the extrapolation of microsomal CLint,
the use of lower or higher estimates of microsome yield
would not substantially alter predictivity.) The use of
human hepatocytes has been promoted for the genera-
tion of in vitro CLint (for example [40]) given the under-
prediction of in vivo CLH using HLM as the enzyme
source. Human kidney microsomes exhibit high activity
towards several UGT2B7 substrates [40] and a contri-
bution of the kidney to metabolic clearance in vivo
would also affect in vitro–in vivo clearance extrapola-
tion based on human liver microsomal kinetic data.
There is no evidence at present for a significant compo-
nent of renal metabolic clearance to AZT elimination in
vivo.
Like Km, the Ki for fluconazole inhibition of human
liver microsomal and UGT2B7-catalysed AZT glucu-
ronidation was reduced by almost 90% in the presence
of BSA. When substituted in equation 6, the Ki values
determined in the absence of BSA did not predict an
interaction between fluconazole and AZT. (Unlike CLint,
the extrapolation of Ki is not dependent on a microsomal
scaling factor.) However, an interaction was predicted
by the Ki generated in the presence of BSA, using both
HLM and UGT2B7 as the enzyme source. The in vivo
AUC ratio was predicted for various concentrations of
fluconazole (see below), and ranged from 1.38 to 2.05
and 1.73 to 3.0 using the Ki determined with HLM and
UGT2B7, respectively. The mean AZT AUC ratio (in
the presence and absence of fluconazole), calculated
from apparent oral clearances via glucuronidation, in
patients coadministered AZT (200 mg 8-hourly) and flu-
conazole (400 mg once daily) is 1.92 [18].
In addition to Ki, the predicted in vivo AUC ratio
depends on the inhibitor concentration, I, at the enzyme
active site. Several estimates of I have been used for in
vitro–in vivo correlation, including total and unbound
drug plasma concentrations, hepatic input concentration
and the concentration in liver tissue [2]. In this work,
unbound concentrations in plasma were used to calcu-
late the AZT AUC ratio (equation 6), since it is generally
assumed that only unbound drug is available to the
enzyme active site. (It should be noted, however, that
since the plasma protein binding of fluconazole is low,
the use of total plasma concentrations increases the AZT
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AUC ratios shown in Table 4 by <10%.) Based on
plasma fluconazole concentrations reported in the flu-
conazole–AZT interaction study [18] and Ki values
determined with HLM (in the presence of BSA) as the
enzyme source, inclusion of maximum and average
unbound fluconazole concentrations in equation 6
under-estimated the known mean increase in AZT AUC
by 47% and 59%, respectively. The use of the hepatic
input concentration has been recommended as a mea-
sure of I [5, 11, 41] but, as shown in equation 7, calcu-
lation of this parameter requires additional data,
particularly the absorption rate constant (ka). Three val-
ues of ka were used to estimate Iinlet,u: the mean and
maximum reported absorption rate constants for flucon-
azole [35] and the theoretical maximum (0.1 min−1) [5].
The predicted increases in the AZT AUCs calculated
using inhibitor concentrations based on the experimen-
tal rate constants were lower than the mean in vivo value
(by 28–36%), whereas use of the theoretical maximum
absorption rate constant marginally overestimated the
magnitude of the in vivo interaction (by 14%).
Interestingly, the Ki value determined with UGT2B7
as the enzyme source (in the presence of BSA) also
predicted inhibition of AZT glucuronidation by flucon-
azole, although the magnitude of the interaction was
generally  over-estimated.  Nevertheless,  this  observa-
tion suggests  that  recombinant  UGTs  may  be  useful
for screening inhibitory interactions between glucu-
ronidated drugs, at least where the selectivity of a
reaction is known.
The addition of BSA to incubations of HLM has
been reported to reduce the Km of a number of drugs
metabolized by CYP2C9 [21–23]. The mechanism of
this effect is unknown, but altered protein conforma-
tion and the ‘mopping up’ of endogenous inhibitors
present in microsomal incubations have been proposed
[23]. In the present study, BSA decreased the Km for
AZT glucuronidation by both HLM and UGT2B7
(expressed in the mammalian HEK293 cell line). It is
possible that components of the commercial BSA
preparation used here, such as globulins and fatty
acids, may contribute to the effect on AZT glucu-
ronidation, as has been demonstrated recently for
CYP2C9 [42]. However, there is recent evidence dem-
onstrating that UGT1A1 binds directly to albumin in
vitro [43], and it might be speculated that an interac-
tion between albumin and UGTs enhances substrate
binding in vitro and in vivo. Although there are simi-
larities between the effects of BSA on CYP2C9 and
UGT2B7 activities, differences are also apparent. The
decrease in the Km of CYP2C9 substrates occurs only
at low BSA concentrations, with reversal of the effect
at  4%  BSA  [23].  In  contrast,  the  effect  of  BSA  on
the activity of UGTB7 was observed to plateau in the
range 2–4%. Studies are underway to elucidate the
mechanism and universality of the effect of BSA and
HSA on xenobiotic glucuronidation.
In summary, fluconazole was shown to be a relatively
selective competitive inhibitor of UGT2B7, consistent
with the inhibitory interaction between AZT and flucon-
azole reported in vivo. The addition of BSA to incuba-
tions decreased the Km for AZT glucuronidation by both
HLM and recombinant UGT2B7, independent of any
effect on protein binding. Similarly, BSA (2%) also
reduced the Ki for inhibition of HLM- and UGT2B7-
catalysed AZT glucuronidation by fluconazole by
almost 90%. The Ki values generated in the presence,
but not absence, of BSA predicted an interaction
between the two drugs to an extent dependent on esti-
mates of the fluconazole concentration in vivo. These
data provide preliminary evidence to suggest that a Ki
value determined in vitro may predict the magnitude of
an inhibitory interaction involving glucuronidated
drugs.
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ient of a Flinders University International Postgraduate
Research Scholarship.
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